In-Vitro Colorectal Cancer Screening Tests Market Size by Test Type (Fecal Occult Blood Tests [Guaiac FOB Stool, Immuno-FOB Agglutination, Lateral Flow Immuno-FOB, Immuno-FOB ELISA], Biomarker Tests [Tumor M2-PK Stool, Transferrin Assays], CRC DNA Screening Tests [Methylated Gene Testing, Panel DNA Tests]), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025

Published Date: Feb 2019  |  Report ID: GMI451  |  Authors: Sumant Ugalmugle

Report Format: PDF   |   Pages: 140   |   Base Year: 2018




Summary Table of Contents Industry Coverage Methodology

Industry Trends

In-Vitro Colorectal Cancer Screening Tests Market size was valued over USD 0.9 billion in 2018 and is expected to witness 5.3% CAGR from 2019 to 2025.
 

In-Vitro Colorectal Cancer Screening Tests Market

Get more details on this report - Request Free Sample PDF
 

Rising incidence of cancer, growing demand for non-invasive disease diagnosis methods along with technological advancements in cancer screening techniques will drive in-vitro colorectal cancer screening tests market over the forecast timeframe.
 

Favourable regulations and cost effectiveness of DNA sequencing will further propel industry growth. U.S. FDA recently approved faecal DNA test and blood test for colorectal cancer screening, thus fulfilling growing consumer demand for minimally invasive screening tests. According to the National Cancer Institute’s statistics, nearly 1,317,247 people in U.S. suffered from colorectal cancer in the year 2014. Moreover, prevalence of colorectal cancer among younger population will stimulate demand for colorectal screening tests during forecast period.
 

Technological advancements including high speed DNA sequencing coupled with cost effectiveness of DNA sequencing will fuel in-vitro colorectal cancer screening tests market. Growing R&D towards developing advanced DNA sequencing methods such as RNAP sequencing, hybridization, microfluidic sanger sequencing and will positively impact market growth. However, scarcity of trained professionals in developing countries, inadequate reimbursement coverage and lack of uniform cancer screening guidelines in Asia Pacific will hinder market growth over the coming years.
 

In-Vitro Colorectal Cancer Screening Tests Market Report Coverage
Report Coverage Details
Base Year: 2018 Market Size in 2018: 0.9 Billion (USD)
Historical Data for: 2014 to 2018 Forecast Period: 2019 to 2025
Forecast Period 2019 to 2025 CAGR: 5.3% 2025 Value Projection: 1.3 Billion (USD)
Pages: 140 Tables, Charts & Figures: 110
Geographies covered (15): U.S., Canada, UK, Germany, France, Italy, Spain, Japan, China, India, Australia, Brazil, Mexico, South Africa, Saudi Arabia
Segments covered: Test Type and Region
Companies covered (19): Abbott Molecular Inc., Alere Inc., Beckman Coulter Inc., Eiken Chemical, Epigenomics AG Corporation, Sysmex Corporation, Siemens Healthcare, Quest Diagnostics Incorporated, CompanianDx, OncoCyte Corporation-Biotime, Merck Millipore, GeneNews Ltd., BioMarCare Technologies Ltd, Immunostics Inc., ExiQon, Kyowa Medex Co. Ltd., Mode Diagnostics, Randox Laboratories Ltd, R-Biopharm Incorporation
Growth Drivers:
  • Improvements in colorectal cancer screening through non-invasive methods
  • Advancements in the field of diagnosis
  • Rising prevalence of colorectal cancer
  • Cost-efficient and High-speed DNA sequencing
Pitfalls & Challenges:
  • Lack of uniform cancer screening guidelines in Asia Pacific
  • Inadequate reimbursement coverage
  • Shortage of trained staff in developing regions

Get more details on this report - Request Free Sample PDF
 

In-Vitro Colorectal Cancer Screening Tests Market, By Test Type

Germany in-vitro colorectal cancer screening tests market by test type

Get more details on this report - Request Free Sample PDF
 

Faecal occult blood test dominated global in-vitro colorectal cancer screening tests market in 2018 by capturing 83.8% share and is estimated to follow similar trend over the forecast timeframe. Growing adoption of faecal occult blood test along with its cost effectiveness will drive market growth. Immuno-FOB Agglutination and Immuno-FOB ELISA tests are revenue generating business segments of faecal occult blood test.
 

Lateral flow Immuno-FOB test market is anticipated to witness considerable growth of 5.8% over the coming years due to its enhanced specificity and sensitivity. It can be used in wide range of settings. Moreover, its low sample volume requirement and ease of use will fuel industry growth.

 

Growing research activities pertaining to development of novel biomarker assays, growing awareness about early disease diagnosis allowing use of diagnostic biomarkers will fuel growth of biomarker test segment over the forecast timeframe. Enzyme biomarker M2-PK been considered as vital enzyme in colorectal cancer and polyps will drive tumor M2-PK stool test segment.
 

In-Vitro Colorectal Cancer Screening Tests Market, By Region

Europe in-vitro colorectal cancer screening tests market by country

Get more details on this report - Request Free Sample PDF
 

U.S. dominated North America in-vitro colorectal cancer screening tests market with revenue of USD 255.4 million in 2018 due to large patient population base, high adoption of sedentary lifestyle and unhealthy food habits. Increasing initiatives undertaken by private and public players to create awareness about disease and diagnostic methods will further drive U.S. in-vitro colorectal cancer screening tests market over the forecast period.
 

High technological adoption, technological advancements in cancer screening techniques and rising incidence of bowel cancer will drive Germany in-vitro colorectal cancer screening tests market. Growing application of screening tests for prevention of bowel cancer coupled with presence of German national statutory cancer screening programme will positively impact market size growth.
 

Japan in-vitro colorectal cancer screening tests market will grow at 6.1% during the forecast period. The country is driven by high disease prevalence, rising demand for cancer screening tests and numerous efforts by government to reduce disease burden. Presence of Cancer Control Act of 2006, improvement in colorectal cancer screening will further propel industry growth.
 

Growing prevalence of colorectal cancer coupled with several initiatives undertaken by government to reduce disease burden will drive Brazil in-vitro colorectal cancer screening tests market. Initiatives such as colorectal cancer (CRC) screening program and Brazilian Association of Intestinal Cancer Prevention (ABRAPRECI) program will positively impact market growth.
 

Competitive Market Share

Few notable players of global in-vitro colorectal cancer screening tests market are EMD Millipore, Siemens Healthcare, Qiagen, Alere and Beckman Coulter. Industry players are engaged in research and development activities to develop tests with superior specificity and sensitivity with relative low price to gain significant market share. New product development, strategic collaboration and expansion through setting up new manufacturing facilities are some of the strategies adopted by market players to consolidate their market position. Other active players in the market include Abbott Molecular, Epigenomics AG, Sysmex Corporation, Eiken Chemical Quest Diagnostics, OncoCyte Corporation-Bio time, BioMarCare Technologies, Novigenix, Randox Laboratories, Exact Sciences Corporation, Immunostics, GeneNews, Kyowa Medex, and R-Biopharm Incorporation.
 

In-Vitro Colorectal Cancer Screening Tests Industry Background  

Growing incidence of colorectal cancer globally along with rising disease awareness due to numerous initiatives undertaken by public and private players will drive in-vitro colorectal cancer screening tests market. Industry players are focusing on developing low cost cancer screening tests with enhanced sensitivity and specificity to gain significant market share along with sustaining their market position. Technological advancements in field of genomics, next generation DNA sequencing and growing demand for minimal invasive techniques for disease screening will positively impact market growth. Market players such as Alere are adopting various expansion strategies to gain significant market share in emerging markets.  For instance, Alere established new manufacturing facility in India in April 2016.
 


Buy NowImmediate delivery available

Need a Discount? Get in touch with us for special pricing

Request Discount

Connect with our sales team

Premium Report Details

  • Published Date: Feb 2019
  • Pages: 140
  • Tables: 104
  • Charts / Figures: 6
  • Companies covered: 19
  • Countries covered: 15

Benefits of Association

Data Coverage & Quality

GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.

Client Trust & Security

GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.

Customer Service

Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.

GMIPulse, our report store

We have introduced ‘GMIPulse’, which is our report store; designed to offer clients a one-stop platform for all market research and business intelligence requirements. Clients can access reports, presentations, raw data excel sheets as well as detailed company profiles. GMIPulse allows you to track relevant industries and stay informed with latest innovation, competitive and regulatory developments to help design strategic framework.

Chat with us
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. More info X